568 related articles for article (PubMed ID: 33754044)
1. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.
Shi R; Bao X; Unger K; Sun J; Lu S; Manapov F; Wang X; Belka C; Li M
Theranostics; 2021; 11(10):5061-5076. PubMed ID: 33754044
[No Abstract] [Full Text] [Related]
2. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
[No Abstract] [Full Text] [Related]
4. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis and Reinforcement Learning of Hypoxic Genes Based on Four Machine Learning Algorithms for Estimating the Immune Landscape, Clinical Outcomes, and Therapeutic Implications in Patients With Lung Adenocarcinoma.
Sun Z; Zeng Y; Yuan T; Chen X; Wang H; Ma X
Front Immunol; 2022; 13():906889. PubMed ID: 35757722
[TBL] [Abstract][Full Text] [Related]
7. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
[TBL] [Abstract][Full Text] [Related]
8. Eight-gene signature predicts recurrence in lung adenocarcinoma.
Zhang Y; Fan Q; Guo Y; Zhu K
Cancer Biomark; 2020; 28(4):447-457. PubMed ID: 32508318
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma.
Wang J; He L; Tang Y; Li D; Yang Y; Zeng Z
Aging (Albany NY); 2020 Nov; 12(22):23200-23216. PubMed ID: 33221751
[TBL] [Abstract][Full Text] [Related]
10. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
11. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
12. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
13. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
Wang Z; Chen X
Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
[TBL] [Abstract][Full Text] [Related]
14. Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma.
Song Y; Chen D; Zhang X; Luo Y; Li S
Thorac Cancer; 2019 May; 10(5):1220-1228. PubMed ID: 30993904
[TBL] [Abstract][Full Text] [Related]
15. Systematic construction and validation of an epithelial-mesenchymal transition risk model to predict prognosis of lung adenocarcinoma.
Tang Y; Jiang Y; Qing C; Wang J; Zeng Z
Aging (Albany NY); 2020 Dec; 13(1):794-812. PubMed ID: 33340396
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.
Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H
J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136
[TBL] [Abstract][Full Text] [Related]
17. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
[TBL] [Abstract][Full Text] [Related]
18. Gene signatures of 6-methyladenine regulators in women with lung adenocarcinoma and development of a risk scoring system: a retrospective study using the cancer genome atlas database.
Gao C; Zhuang J; Li H; Liu C; Zhou C; Liu L; Feng F; Sun C
Aging (Albany NY); 2021 Jan; 13(3):3957-3968. PubMed ID: 33428597
[TBL] [Abstract][Full Text] [Related]
19. A Recurrence-Specific Gene-Based Prognosis Prediction Model for Lung Adenocarcinoma through Machine Learning Algorithm.
Xu S; Zhou J; Liu K; Chen Z; He Z
Biomed Res Int; 2020; 2020():9124792. PubMed ID: 33224985
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.
Li H; Tong L; Tao H; Liu Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32031203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
